Akero Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
10-K: Akero Therapeutics Reports Continued Losses Amidst Promising Clinical Trials for MASH Treatment
Akero Therapeutics' 10-K filing reveals ongoing financial losses as the company progresses with clinical trials for Efruxifermin (EFX), a potential treatment for Metabolic dysfunction-associated steatohepatitis (MASH).
Akero Therapeutics, a clinical-stage biotech company, released its 2023 financial results and provided an update on its lead drug candidate, efruxifermin (EFX), for treating metabolic dysfunction-associated steatohepatitis (MASH).